Asterias Biotherapeutics (AST) Stock Price, News & Analysis

Company Overview

Asterias Biotherapeutics, Inc. is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel pluripotent cell therapies to treat serious diseases and injuries. The company’s core technology platform leverages allogeneic human embryonic stem cells (hESCs) that have been carefully differentiated into target cell types. By employing proprietary manufacturing processes, Asterias aims to deliver precise cell populations that can engraft effectively, modulate tissue repair, and restore function in damaged organs.

The company’s most advanced program, AST‐OPC1, consists of oligodendrocyte progenitor cells intended to treat acute spinal cord injury. Asterias has completed multiple cohorts in Phase 1/2 clinical trials, evaluating the safety and preliminary efficacy of AST‐OPC1 in patients with cervical spinal cord lesions. Beyond spinal repair, Asterias maintains a preclinical pipeline exploring additional neurological and ophthalmic indications, leveraging its expertise in stem cell differentiation and immunomodulation.

Founded in 2013 as a spin‐out from Geron Corporation, Asterias is headquartered in Fremont, California, and operates state‐of‐the‐art cell manufacturing facilities in the San Francisco Bay Area. Since its initial public offering on the NYSE American exchange, the company has pursued orphan drug and regenerative medicine designations with the U.S. Food and Drug Administration, forging collaborations with academic centers and research consortia to advance translational science and optimize clinical trial design.

Under the guidance of a seasoned executive team and board of directors with deep experience in regenerative medicine and biotechnology, Asterias Biotherapeutics continues to refine its manufacturing platform, expand its intellectual property portfolio, and engage in strategic partnerships. With a clear focus on cell‐based therapeutics for unmet medical needs, the company is positioned to bring first‐in‐class treatments from its laboratory to patients in North America and beyond.

Key Stats

• Today's Range: $0.0020 to $0.0020
• 50-Day Range: N/A
• 52-Week Range: $0.51 to $2.05
• Volume: 1,000 shs
• Average Volume: 136,653 shs
• Market Capitalization: $111.32 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AST Stock Analysis - Frequently Asked Questions

How have AST shares performed this year?

Asterias Biotherapeutics' stock was trading at $0.0020 at the beginning of 2025. Since then, AST shares have increased by 0.0% and is now trading at $0.0020.

How were Asterias Biotherapeutics' earnings last quarter?

Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) issued its earnings results on Tuesday, March, 28th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by $0.01. The biotechnology company earned $1.75 million during the quarter, compared to analysts' expectations of $2.81 million.

How do I buy shares of Asterias Biotherapeutics?

Shares of AST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Asterias Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Asterias Biotherapeutics investors own include Zynerba Pharmaceuticals (ZYNE), CorMedix (CRMD), Synergy Pharmaceuticals (SGYP), 22nd Century Group (XXII), Amarin (AMRN), Gilead Sciences (GILD) and Progenics Pharmaceuticals (PGNX).

Company Calendar

• Last Earnings: 3/28/2017
• Today: 7/19/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NYSEAMERICAN:AST
• Previous Symbol: NYSEMKT:AST
• CIK: N/A
• Web: asteriasbiotherapeutics.com
• Phone: +1-510-4563805
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 55,659,000
• Free Float: N/A
• Market Cap: $111.32 thousand
• Optionable: Not Optionable
• Beta: N/A